Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Audrey SimonaggioR ElaidiL FournierE FabreV FerrariD BorchielliniJ ThouveninP BarthelemyC ThibaultE TartourS OudardY A VanoPublished in: Cancer immunology, immunotherapy : CII (2020)
Any NLR increase at week 6 was associated with worse PFS and OS outcomes. NLR variation is an inexpensive and dynamic marker easily obtained to monitor anti-PD1 efficacy.